Zoekresultaten - Tadeusz Robak

Verfijn jouw resultaten
  1. 1
    Second Malignancies and Richter's Syndrome in Patients with Chronic Lymphocytic Leukemia

    Second Malignancies and Richter's Syndrome in Patients with Chronic Lymphocytic Leukemia door Tadeusz Robak

    Gepubliceerd in 2004
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2)

    Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospectiv... door Tadeusz Robak

    Gepubliceerd in 2006
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    Pharmacogenomics of<i>MDR1</i>/<i>ABCB1</i>Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies

    Pharmacogenomics of<i>MDR1</i>/<i>ABCB1</i>Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies door Krzysztof Jamroziak, Tadeusz Robak

    Gepubliceerd in 2004
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  4. 4
    Safety and Tolerability of Antibody-Drug Conjugates in Cancer

    Safety and Tolerability of Antibody-Drug Conjugates in Cancer door Anna Wolska, Tadeusz Robak

    Gepubliceerd in 2019
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  5. 5
    Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later

    Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later door Paweł Robak, Tadeusz Robak

    Gepubliceerd in 2019
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  6. 6
    Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives

    Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives door Ewa Robak, Tadeusz Robak

    Gepubliceerd in 2022
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  7. 7
    The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions

    The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions door Tadeusz Robak, Magdalena Witkowska, Piotr Smolewski

    Gepubliceerd in 2022
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  8. 8
    PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives

    PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives door Iwona Hus, Bartosz Puła, Tadeusz Robak

    Gepubliceerd in 2022
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  9. 9
    Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need

    Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need door Przemysław Zygmunciak, Tadeusz Robak, Bartosz Puła

    Gepubliceerd in 2024
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  10. 10
    Toll-like receptors and their role in carcinogenesis and anti-tumor treatment

    Toll-like receptors and their role in carcinogenesis and anti-tumor treatment door Anna Wolska, Ewa Lech‐Marańda, Tadeusz Robak

    Gepubliceerd in 2008
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  11. 11
    Serum levels of interleukin‐6 type cytokines and soluble interleukin‐6 receptor in patients with rheumatoid arthritis

    Serum levels of interleukin‐6 type cytokines and soluble interleukin‐6 receptor in patients with rheumatoid arthritis door Tadeusz Robak, A Gladalska, H Stępień, Ewa Robak

    Gepubliceerd in 1998
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  12. 12
    Extramedullary and extranodal manifestations in chronic lymphocytic leukemia – an update

    Extramedullary and extranodal manifestations in chronic lymphocytic leukemia – an update door Tadeusz Robak, Anna Puła, Marcin Braun, Ewa Robak

    Gepubliceerd in 2024
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  13. 13
    Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases

    Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases door Tadeusz Robak, Anna Korycka, Ewa Lech‐Marańda, Paweł Robak

    Gepubliceerd in 2009
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  14. 14
    Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up door Barbara Eichhorst, Martin Dreyling, Tadeusz Robak, Emili Montserrat, Michael Hallek

    Gepubliceerd in 2011
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  15. 15
    Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up door Tadeusz Robak, Estella Matutes, Daniel Catovsky, Pier Luigi Zinzani, Christian Buske

    Gepubliceerd in 2015
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  16. 16
    Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus

    Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus door Agnieszka Klonowska-Szymczyk, Anna Wolska, Tadeusz Robak, Barbara Cebula‐Obrzut, Piotr Smolewski, Ewa Robak

    Gepubliceerd in 2014
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  17. 17
    Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

    Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia door Peter Hillmen, Aleksander B. Skotnicki, Tadeusz Robak, Branimir Jakšić, Anna Dmoszyńska, Jingyang Wu, Cynthia A. Sirard, Jiřı́ Mayer

    Gepubliceerd in 2007
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  18. 18
    Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

    Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide th... door Pieter Sonneveld, Roman Hájek, Arnon Nagler, Andrew Spencer, Joan Bladé, Tadeusz Robak, Sen Hong Zhuang, Jean‐Luc Harousseau, Robert Z. Orlowski

    Gepubliceerd in 2008
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  19. 19
    High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies

    High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies door Peter Dreger, Paolo Ghia, Johannes Schetelig, Michel van Gelder, Eva Kimby, Mauricette Michallet, Carol Moreno, Tadeusz Robak, Stephan Stilgenbauer, Emili Montserrat

    Gepubliceerd in 2018
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  20. 20
    Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis

    Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis door Michael Wang, Tadeusz Robak, Kami J. Maddocks, Tycel Phillips, Stephen D. Smith, David Gallinson, Roser Calvo, Chuan‐Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak

    Gepubliceerd in 2024
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: